| HOME >> BIOLOGY >> TECHNOLOGY |
NANJING, China, Nov. 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today its participation in the Morgan Stanley 7th Annual Asia Pacific Summit 2008. The conference will be held at the Mandarin Oriental Singapore on November 11-13, 2008.
Simcere's chief financial officer, Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attend the conference on Wednesday November 12. Frank Zhigang Zhao will give a company presentation to investors at 11:30am, which will take place on Amber Track, Level 1 of Mandarin Oriental Singapore. A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's website, located at http://www.simcere.com.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading
manufacturer and supplier of branded generic pharmaceuticals and
manufacturer of the patented anti-cancer biotech product Endu in the
rapidly growing China market. In recent years, Simcere has been focusing
its strategy on the development of first-to-market generic and innovative
pharmaceuticals, and has introduced a first-to-market generic stroke
management medication under the brand name Bicun and an innovative
anti-cancer medication under the brand name Endu. Simcere currently
manufac
'/>"/>
| SOURCE Simcere Pharmaceutical Group Copyright©2008 PR Newswire. All rights reserved |